Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
anbalcabtagene autoleucel
- Development stage
- Phase 2
- Lead developer
- Curocell
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
Anbalcabtagene autoleucel (Anbal-cel) is a next-generation autologous CD19-directed chimeric antigen receptor (CAR)-T cell therapy developed using Curocell’s OVIS platform. It uniquely incorporates knock-downs of both PD-1 (programmed cell death protein 1) and TIGIT (T cell immunoglobulin and ITIM domains), which are immune checkpoint receptors implicated in T cell exhaustion. By reducing the expression of these inhibitory molecules, Anbal-cel aims to enhance CAR-T cell persistence and antitumor efficacy versus conventional anti-CD19 CAR-T therapies. It has demonstrated superior eradication of CD19-positive tumor cells in preclinical studies, and early clinical trials show promising efficacy and a tolerable safety profile. Its primary development indications include relapsed/refractory large B-cell lymphoma, follicular lymphoma, central nervous system lymphoma, and high-grade B-cell lymphoma[1][5][9].
- Brand names
- Anbal-cel
- Other names
- anbal-cel
02
Targets
CD19 (B lymphocyte antigen CD19)PDCD1 (Programmed cell death protein 1 receptor)TIGIT (T cell immunoreceptor with Ig and ITIM domains)
Beyond the preview
Go deeper on anbalcabtagene autoleucel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on anbalcabtagene autoleucel.